Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Bibliographic Details
Main Authors: Wu‐tong Ju, Ying Liu, Li‐zhen Wang, Jiang Li, Guo‐xing Ren, Jian Sun, Wen‐yong Tu, Yong‐jie Hu, Tong Ji, Wen‐jun Yang, Jun Li, Yue He, Yan‐an Wang, Chen‐ping Zhang, Lai‐ping Zhong, Zhi‐yuan Zhang
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Communications
Online Access:https://doi.org/10.1002/cac2.12136

Internet

https://doi.org/10.1002/cac2.12136

Similar Items